Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
Public ClinicalTrials.gov record NCT01571284. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Single Arm, Open Label Clinical Trial to Evaluate the Safety and Health-Related Quality of Life of Aflibercept in Patients With Metastatic Colorectal Cancer (mCRC) Previously Treated With an Oxaliplatin-Containing Regimen
Study identification
- NCT ID
- NCT01571284
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Sanofi
- Industry
- Enrollment
- 781 participants
Conditions and interventions
Conditions
Interventions
- AFLIBERCEPT AVE0005 Drug
- FOLFIRI Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 29, 2012
- Primary completion
- Jan 30, 2017
- Completion
- Jan 30, 2017
- Last update posted
- Apr 16, 2018
2012 – 2017
United States locations
- U.S. sites
- 12
- U.S. states
- 9
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigational Site Number 840-002 | Muscle Shoals | Alabama | 35661 | — |
| Investigational Site Number 840-008 | Corona | California | 92879 | — |
| Investigational Site Number 840-007 | Fountain Valley | California | 92708 | — |
| Investigational Site Number 840-004 | Riverside | California | 92501 | — |
| Investigational Site Number 840-006 | Indianapolis | Indiana | 46254 | — |
| Investigational Site Number 840-011 | Metairie | Louisiana | 70006 | — |
| Investigational Site Number 840-001 | Rockville | Maryland | 20850 | — |
| Investigational Site Number 840-010 | Howell Township | New Jersey | 07731 | — |
| Investigational Site Number 840-012 | Albuquerque | New Mexico | 87106 | — |
| Investigational Site Number 840-009 | Farmington | New Mexico | 87401 | — |
| Investigational Site Number 840-003 | Lake Success | New York | 11042 | — |
| Investigational Site Number 840-005 | Middletown | Ohio | 45042 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 167 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01571284, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 16, 2018 · Synced Jun 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01571284 live on ClinicalTrials.gov.